Karl J. Puttlitz

Array ( [id] => 19608902 [patent_doc_number] => 12157768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-03 [patent_title] => Anti-LILRB2 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/276324 [patent_app_country] => US [patent_app_date] => 2019-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 106 [patent_figures_cnt] => 137 [patent_no_of_words] => 63389 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 912 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20254868 [patent_doc_number] => 12427201 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates [patent_app_type] => utility [patent_app_number] => 16/572557 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 50 [patent_no_of_words] => 42438 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 752 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16572557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221344 [patent_doc_number] => 20200246460 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same [patent_app_type] => utility [patent_app_number] => 16/563507 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 122354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16563507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19226725 [patent_doc_number] => 12006358 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Antibody against advanced glycation end products and use thereof [patent_app_type] => utility [patent_app_number] => 17/271381 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 38 [patent_no_of_words] => 27849 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15175237 [patent_doc_number] => 20190358210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => 3-ALKYL PYRIDINIUM COMPOUND FROM RED SEA SPONGE WITH POTENT ANTIVIRAL ACTIVITY [patent_app_type] => utility [patent_app_number] => 16/537244 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16537244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435229 [patent_doc_number] => 20200031798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/534903 [patent_app_country] => US [patent_app_date] => 2019-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16534903 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19536677 [patent_doc_number] => 12129218 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-29 [patent_title] => AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same [patent_app_type] => utility [patent_app_number] => 17/262157 [patent_app_country] => US [patent_app_date] => 2019-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 17181 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17262157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340307 [patent_doc_number] => 20230132256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/259466 [patent_app_country] => US [patent_app_date] => 2019-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17259466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067289 [patent_doc_number] => 20210269504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => PROTEIN-BASED MICELLES FOR THE DELIVERY OF HYDROPHOBIC ACTIVE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/258250 [patent_app_country] => US [patent_app_date] => 2019-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17258250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17726617 [patent_doc_number] => 11382982 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-12 [patent_title] => Duocarmycin ADCs showing improved in vivo antitumor activity [patent_app_type] => utility [patent_app_number] => 16/456177 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 6303 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16456177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18311971 [patent_doc_number] => 20230115871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS [patent_app_type] => utility [patent_app_number] => 17/622360 [patent_app_country] => US [patent_app_date] => 2019-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17622360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020951 [patent_doc_number] => 20210244822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => CONJUGATES WITH INTERNAL AND TERMINAL-END HEPAROSAN LINKAGES [patent_app_type] => utility [patent_app_number] => 17/251147 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15024103 [patent_doc_number] => 20190323056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => Diagnostic System and Process for Rapid Bacterial Infection Diagnosis [patent_app_type] => utility [patent_app_number] => 16/437624 [patent_app_country] => US [patent_app_date] => 2019-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16437624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070536 [patent_doc_number] => 11529352 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Preservation of immune response during chemotherapy regimens [patent_app_type] => utility [patent_app_number] => 16/432244 [patent_app_country] => US [patent_app_date] => 2019-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 41 [patent_no_of_words] => 49964 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16432244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990279 [patent_doc_number] => 20210228699 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => COMPOSITIONS AND METHODS FOR TARGETED IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 15/734116 [patent_app_country] => US [patent_app_date] => 2019-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18048 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734116 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15144933 [patent_doc_number] => 20190350944 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/423976 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16423976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858499 [patent_doc_number] => 11439637 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use [patent_app_type] => utility [patent_app_number] => 16/419971 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 15 [patent_no_of_words] => 42967 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16419971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532456 [patent_doc_number] => 20220111065 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => MOLECULAR ADJUVANT [patent_app_type] => utility [patent_app_number] => 17/057486 [patent_app_country] => US [patent_app_date] => 2019-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15243483 [patent_doc_number] => 10507251 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-17 [patent_title] => Anti-human MUC1 antibody fab fragment [patent_app_type] => utility [patent_app_number] => 16/414895 [patent_app_country] => US [patent_app_date] => 2019-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 9 [patent_no_of_words] => 21272 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 199 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15144925 [patent_doc_number] => 20190350940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/413719 [patent_app_country] => US [patent_app_date] => 2019-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 264 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16413719 [rel_patent_id] =>[rel_patent_doc_number] =>)